Together with ExpreS2ion Biotechnologies' CEO, Bent Frandsen, we looked back at the main achievements in 2024, which was the first year of implementing the new strategy. The company has focused on leveraging the platform to advance assets with shorter development timelines, and it has also been a year with good progress in the pipeline. In the interview, you can hear more about the progress of the breast cancer candidate, external validation through partnerships, and lastly which milestones investors should look out for in 2025.Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 11:27, 18 December 2024.

info@inderes.fi (inderes.fi)

© Inderes Oyj. All rights reserved.